✦ LIBER ✦

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

✍ Scribed by Weisberg, Ellen; Manley, Paul W.; Cowan-Jacob, Sandra W.; Hochhaus, Andreas; Griffin, James D.

Book ID: 109947859
Publisher: Nature Publishing Group
Year: 2007
Tongue: English
Weight: 651 KB
Volume: 7
Category: Article
ISSN: 1474-1776
DOI: 10.1038/nrc2126

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Guidelines for the measurement of BCR-AB

Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia

✍ Letizia Foroni; Gill Wilson; Gareth Gerrard; Joanne Mason; David Grimwade; Helen 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

Advances in the structural biology, desi

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

✍ Paul William Manley; Sandra W. Cowan-Jacob; Jürgen Mestan 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 373 KB

Dynamic change of T315I BCR-ABL kinase d

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors

✍ Wan-Seok Kim; Dongho Kim; Dong-Wook Kim; Il-Young Kweon; Soo-Hyun Kim; Hyun-Gyun 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB 👁 1 views

## Abstract We analysed the dynamic change of imatinib‐resistant mutations in BCR‐ABL kinase domain focusing on T315I mutation during dasatinib or nilotinib therapy. Fifty‐five imatinib‐resistant chronic myeloid leukaemia patients (32 patients with imatinib‐resistant mutations and 23 patients witho

Cost–utility analysis of imatinib mesila

Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia

✍ Gordois, A; Scuffham, P; Warren, E; Ward, S 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 107 KB

Beneficial effects of combining a type I

Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML

✍ Weisberg, E; Deng, X; Choi, H G; Barrett, R; Adamia, S; Ray, A; Moreno, D; Kung, 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 521 KB

Choosing the best treatment strategy for

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history

✍ Jabbour, E; Hochhaus, A; Cortes, J; La Rosée, P; Kantarjian, H M 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 326 KB